Adverse events of targeted therapies reported by patients with cancer treated in primary care.
Aged
Drug-Related Side Effects and Adverse Reactions
/ epidemiology
France
/ epidemiology
Humans
Interviews as Topic
Middle Aged
Molecular Targeted Therapy
/ adverse effects
Neoplasms
/ drug therapy
Primary Health Care
Prospective Studies
Qualitative Research
Quality of Life
Surveys and Questionnaires
Adverse effect
ambulatory monitoring
cancer survivors
questionnaire
targeted therapies
Journal
The European journal of general practice
ISSN: 1751-1402
Titre abrégé: Eur J Gen Pract
Pays: England
ID NLM: 9513566
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
5
1
2021
pubmed:
6
1
2021
medline:
15
10
2021
Statut:
ppublish
Résumé
Targeted Therapies (TT) are among the therapeutic innovations for cancer treatment in outpatient settings. TT-related Adverse Events (AEs) are a source of loss of opportunity for patients if their management is inappropriate. The objective of this study was to describe the AE frequency and severity as reported by patients with cancer who received TT in ambulatory settings. A second objective was to describe the role of the general practitioner (GP) in the management of AEs. All patients who started TT at a French Regional Cancer Centre in 2017-2018 were eligible for this 12-month prospective study. A self-administered questionnaire was distributed at inclusion and returned after three months. In the questionnaire, patients listed all AEs that occurred during this period and rated their severity. Occurrence and severity were compared with the rating by a specialised nurse. Patients also indicated the health professional they contacted first for the reported AE. Among the 247 eligible patients, 15 were excluded and 144 responded to the questionnaire. Fourteen different TTs have been prescribed. Asthenia (92.4%) and anorexia (64.6%) were the most frequent AE. Patients' AE severity rating was more severe than the nurse's rating for all drugs ( Patients experienced an average of 4 AEs. AE severity rating was significantly different between patients and nurses. Patients do not always communicate AEs to health care professionals.
Sections du résumé
BACKGROUND
BACKGROUND
Targeted Therapies (TT) are among the therapeutic innovations for cancer treatment in outpatient settings. TT-related Adverse Events (AEs) are a source of loss of opportunity for patients if their management is inappropriate.
OBJECTIVES
OBJECTIVE
The objective of this study was to describe the AE frequency and severity as reported by patients with cancer who received TT in ambulatory settings. A second objective was to describe the role of the general practitioner (GP) in the management of AEs.
METHODS
METHODS
All patients who started TT at a French Regional Cancer Centre in 2017-2018 were eligible for this 12-month prospective study. A self-administered questionnaire was distributed at inclusion and returned after three months. In the questionnaire, patients listed all AEs that occurred during this period and rated their severity. Occurrence and severity were compared with the rating by a specialised nurse. Patients also indicated the health professional they contacted first for the reported AE.
RESULTS
RESULTS
Among the 247 eligible patients, 15 were excluded and 144 responded to the questionnaire. Fourteen different TTs have been prescribed. Asthenia (92.4%) and anorexia (64.6%) were the most frequent AE. Patients' AE severity rating was more severe than the nurse's rating for all drugs (
CONCLUSION
CONCLUSIONS
Patients experienced an average of 4 AEs. AE severity rating was significantly different between patients and nurses. Patients do not always communicate AEs to health care professionals.
Identifiants
pubmed: 33399025
doi: 10.1080/13814788.2020.1846713
pmc: PMC7801082
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
202-209Références
Qual Life Res. 2008 Nov;17(9):1125-35
pubmed: 18836850
Br J Cancer. 2017 Mar 28;116(7):849-858
pubmed: 28196066
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Sante Publique. 2004 Sep;16(3):509-20
pubmed: 15625806
Br J Gen Pract. 2005 Oct;55(519):741-2
pubmed: 16212847
J Clin Oncol. 2004 Sep 1;22(17):3485-90
pubmed: 15337796
Eur J Cancer Care (Engl). 1996 Jun;5(2 Suppl):24-30
pubmed: 9117040
J Clin Oncol. 2015 Mar 10;33(8):910-5
pubmed: 25624439
Clin Lung Cancer. 2006 Sep;8(2):99-109
pubmed: 17026810
Breast Cancer Res. 2016 Jun 28;18(1):67
pubmed: 27349747
Cancer Nurs. 2018 Sep/Oct;41(5):418-423
pubmed: 28731881
Lancet Oncol. 2015 Sep;16(12):1231-72
pubmed: 26431866
Support Care Cancer. 2016 Jun;24(6):2473-9
pubmed: 26667626
BMC Fam Pract. 2012 Jun 19;13:60
pubmed: 22712888
Eur J Gen Pract. 2018 Dec;24(1):171-176
pubmed: 29952234
Eur J Gen Pract. 2017 Dec;23(1):155-163
pubmed: 28554220
Acta Oncol. 2017 Feb;56(2):232-238
pubmed: 28080181
Support Care Cancer. 2015 Dec;23(12):3473-80
pubmed: 25814443
Fam Pract. 2017 Aug 1;34(4):473-478
pubmed: 28122847
JAMA Oncol. 2015 Nov;1(8):1051-9
pubmed: 26270597
Support Care Cancer. 2008 Sep;16(9):1075-83
pubmed: 18197437
JAMA. 2019 Jan 22;321(3):306-307
pubmed: 30667494
J R Soc Med. 1999 Nov;92(11):549-52
pubmed: 10703488
N Engl J Med. 2015 Jul 16;373(3):209-19
pubmed: 26030518
J Clin Oncol. 2014 May 10;32(14):1480-501
pubmed: 24711559
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):e192-e194
pubmed: 26559518
JBI Database System Rev Implement Rep. 2015 Jun 12;13(5):131-204
pubmed: 26455609
Support Care Cancer. 2015 Aug;23(8):2231-44
pubmed: 25564221
J Clin Oncol. 2011 Jul 20;29(21):2910-7
pubmed: 21690465